Generation 3 Triple agonist (GLP-1 + GIP + Glucagon): Retatrutide targets all three
Your friends and family will likely be less critical of your body
Seek urgent medical advice if you experience persistent or severe vomiting, signs of dehydration, or severe upper abdominal pain particularly pain radiating to the back as these may indicate serious complications such as acute pancreatitis
Oral semaglutide targets only the GLP-1 receptor, whereas tirzepatide targets both the GLP-1 and the GIP receptors
Image: Shutterstock February 15, 2024 11:21 AM ESTUpdated February 16, 04:41 AM R&D In Focus Ayisha Sharma News Reporter Katherine Lewin News Reporter Novo Nordisk and Eli Lilly are set to make billions of dollars each year off their GLP-1s, but patients and prescribers are still eager for Sign up to read this article for free
GLP-1 drugs are a class of medications used to treat obesity and type 2 diabetes that include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)